Monte Rosa Therapeutics Inc (GLUE)

Jan 21, 2025

Barclays PLC Acquires 43,499 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Jan 21, 2025

Jan 21, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - Defense World

Jan 21, 2025

Jan 20, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update - MarketBeat

Jan 20, 2025

Jan 15, 2025

Jane Street Group LLC Sells 51,005 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Jan 15, 2025

Jan 11, 2025

Monte Rosa Therapeutics provide corporate update, key milestones 2025 - Yahoo Finance

Jan 11, 2025

Jan 11, 2025

(GLUE) Technical Data - Stock Traders Daily

Jan 11, 2025

Jan 10, 2025

Monte Rosa outlines 2025 clinical milestones - Investing.com India

Jan 10, 2025

Jan 10, 2025

Monte Rosa outlines 2025 clinical milestones By Investing.com - Investing.com Australia

Jan 10, 2025

Jan 10, 2025

Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength - TipRanks

Jan 10, 2025

Jan 10, 2025

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - The Manila Times

Jan 10, 2025

Jan 06, 2025

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 06, 2025

Jan 06, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Acquired by Barclays PLC - Defense World

Jan 06, 2025

Jan 05, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Acquired by Geode Capital Management LLC - Defense World

Jan 05, 2025

Jan 05, 2025

Geode Capital Management LLC Purchases 197,247 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - MarketBeat

Jan 05, 2025

Dec 31, 2024

State Street Corp Raises Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Dec 31, 2024

Dec 23, 2024

Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance

Dec 23, 2024

Dec 22, 2024

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Dec 22, 2024

Dec 20, 2024

Wells Fargo Downgrades Monte Rosa Therapeutics (GLUE) - MSN

Dec 20, 2024

Dec 19, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Cut to Equal Weight at Wells Fargo & Company - MarketBeat

Dec 19, 2024

Dec 17, 2024

Charles Schwab Investment Management Inc. Boosts Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Dec 17, 2024

Dec 14, 2024

The Manufacturers Life Insurance Company Buys 15,168 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Dec 14, 2024

Dec 13, 2024

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Marketscreener.com

Dec 13, 2024

Dec 13, 2024

Monte Rosa Therapeutics appoints new board member - Investing.com

Dec 13, 2024

Dec 13, 2024

Monte Rosa Therapeutics appoints new board member By Investing.com - Investing.com UK

Dec 13, 2024

Dec 13, 2024

Monte Rosa Therapeutics Strengthens Board with Teva's R&D Chief, Advancing Molecular Glue Platform - StockTitan

Dec 13, 2024

Dec 12, 2024

Monte Rosa reports promising cancer therapy results By Investing.com - Investing.com Nigeria

Dec 12, 2024

Dec 11, 2024

Monte Rosa reports promising cancer therapy results - Investing.com

Dec 11, 2024

Dec 11, 2024

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - The Manila Times

Dec 11, 2024

Dec 11, 2024

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - The Manila Times

Dec 11, 2024

Dec 11, 2024

Monte Rosa Therapeutics Announces Closing of Global License - GlobeNewswire

Dec 11, 2024

Dec 11, 2024

Monte Rosa Therapeutics Presents Preclinical Data at the - GlobeNewswire

Dec 11, 2024

Dec 11, 2024

Monte Rosa's Breakthrough Cancer Drug Shows Promise in Preclinical Data, Superior to Current Inhibitors - StockTitan

Dec 11, 2024

Dec 09, 2024

Intech Investment Management LLC Makes New $77,000 Investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Dec 09, 2024

Dec 09, 2024

The 2nd Dimension: VC raises $500M fund for entrepreneurs pioneering life sci, tech - Fierce Biotech

Dec 09, 2024

Dec 07, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 8.7%Here's What Happened - MarketBeat

Dec 07, 2024

Dec 06, 2024

Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study - Yahoo Finance

Dec 06, 2024

Dec 06, 2024

Monte Rosa Therapeutics (GLUE) Price Target Increased by 5.66% to 16.32 - MSN

Dec 06, 2024

Dec 05, 2024

Monte Rosa reports favorable MRT-2359 trial results By Investing.com - Investing.com Nigeria

Dec 05, 2024

Dec 05, 2024

Monte Rosa reports favorable MRT-2359 trial results - Investing.com India

Dec 05, 2024

Dec 05, 2024

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors - The Manila Times

Dec 05, 2024

Dec 05, 2024

Monte Rosa's Cancer Drug MRT-2359 Shows Promising Safety Profile in Phase 1/2 Trial - StockTitan

Dec 05, 2024

Dec 04, 2024

Monte Rosa Therapeutics: A First Assessment (NASDAQ:GLUE) - Seeking Alpha

Dec 04, 2024

Dec 04, 2024

Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? - MSN

Dec 04, 2024

Nov 26, 2024

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - The Manila Times

Nov 26, 2024

Nov 26, 2024

Monte Rosa Therapeutics CEO to Present at Piper Sandler Healthcare Conference | GLUE Stock News - StockTitan

Nov 26, 2024